Rationale and design of NUDGE-CKD: A nationwide randomized factorial trial of electronic nudges for increasing guideline-directed medical therapy in chronic kidney disease
Rationale and design of NUDGE-CKD: A nationwide randomized factorial trial of electronic nudges for increasing guideline-directed medical therapy in chronic kidney disease
Jesper Nørgaard Bech, Brian Lee Claggett, Rikke Borg, Kristoffer Grundtvig Skaarup et al.
Citations
1 citations
Journal
American Heart Journal
Topics
Diabetes Treatment and Management
Field-Weighted Citation Impact (FWCI)
1.29
article
Rationale and design of NUDGE-CKD: A nationwide randomized factorial trial of electronic nudges for increasing guideline-directed medical therapy in chronic kidney disease
Jesper Nørgaard Bech, Brian Lee Claggett, Rikke Borg, Kristoffer Grundtvig Skaarup, Anne Møller, Mats Christian Højbjerg Lassen, Jens‐Ulrik Stæhr Jensen, Lisbet Brandi, Henrik Birn, Harriette Van Spall, Anne Daugaard Thuesen, My Svensson, Jan Kampmann, Michael Knudsen, Mads Hornum, Ankeet S. Bhatt, Muthiah Vaduganathan, Daniel Modin, Ditte Hansen, Kira Hyldekær Janstrup, Morten Lindhardt, Niklas Dyrby Johansen, Tor Biering‐Sørensen, Tilde Kristensen, Scott D. Solomon, Faiez Zannad, Birgitte Ørts
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
American Heart JournalVol. 287
Institutions
University of Copenhagen (DK), Brigham and Women's Hospital (US), Harvard University (US), Inserm (FR), University of Southern Denmark (DK), Aarhus University (DK), Aalborg University Hospital (DK), Aarhus University Hospital (DK), Copenhagen University Hospital (DK), Gentofte Hospital (DK), Population Health Research Institute (CA), Zealand University Hospital (DK), Regionshospitalet Viborg (DK), Kaiser Permanente San Francisco Medical Center (US), Hospital South West Jutland (DK), Lillebaelt Hospital (DK), Holbæk Sygehus (DK), Aalborg University (DK), Université de Lorraine (FR)
Funders
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Hjerteforeningen, Boston Scientific Corporation, Acceleron, Cytokinetics, Sarepta Therapeutics, Moderna, Gedeon Richter, Novo Nordisk, Dansk Nefrologisk Selskab, Vifor Pharma, Novo Nordisk Fonden, Servier, Seqirus, National Institutes of Health, Sanofi Pasteur, American Regent, Respicardia, National Heart, Lung, and Blood Institute